Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4353258 | 0.78 | CA1 (0.34) | CA1CA2ALOX15EPHX1LMNA | |
| SCHEMBL222605 | 0.73 | LMNA (0.35) | ALOX15LMNABLMPMP22 | |
| SCHEMBL3586576 | 0.71 | LMNA (0.33) | ALOX15LMNABLMPMP22 | |
| SCHEMBL8312889 | 0.67 | LMNA (0.30) | ALOX15LMNABLMPMP22 | |
| SCHEMBL10981190 | 0.61 | CYP1A2 (0.32) | LMNA | |
| Isobutyramide SCHEMBL9687358 | 0.61 | — | — | |
| SCHEMBL1968391 | 0.61 | — | — | |
| Isobutyramide SCHEMBL5469885 | 0.61 | CA1 (0.44) | CA1CA2ALOX15EPHX1LMNA | |
| SCHEMBL3645450 | 0.61 | LMNA (0.35) | ALOX15LMNABLMPMP22 | |
| SCHEMBL18737 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004911-A1 | Silylated oligonucleotide compounds | AVECIA LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| EP-1608669-A1 | SILYLATED OLIGONUCLEOTIDE COMPOUNDS | Avecia Limited (GB) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085454-A1 | SILYLATED OLIGONUCLEOTIDE COMPOUNDS | AVECIA LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004911-A1 | Silylated oligonucleotide compounds | POLR2H, RNGTT, POLR2E | CA1 1783/4885CA2 2728/4885ALOX15 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.